MedDataX Logo

Comparision Efficacy of Carbamazepine & Oxcarbazepine in the Treatment of Trigeminal Neuralgia- a Randomised Clinical Trial

NCT ID: NCT04996199

Last Updated: 2021-10-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

132 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-18

Study Completion Date

2022-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Trigeminal neuralgia is a neuropathic facial pain condition, characterized by unilateral paroxysmal pain which can be described as stabbing or electric shock like, in the distribution of one or more divisions of trigeminal nerve which is triggered by innocuous stimuli. The attack is provoked by touching or stimulating these trigger zones. There are various pharmacological drugs present for the treatment of trigeminal neuralgia. Carbamazepine and oxcarbazepine are the first-choice drugs for the treatment of TN. Other drugs include lamotrigine , baclofen , gabapentin, antidepressants , eslicarbazepine , sumatriptan \& vixitrigine. The carbamazepine is first choice of drug which has serious side effects including dizziness, memory loss, sleppiness, aplastic anaemia. Oxcarbazepine has similar mechanism of action and found to have lesser adverse events when used in various neuralgias in the place of carbamazepine. But there is still lack of evidence to prove that oxcarbazepine can be used as monotherapy in TN patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Trigeminal neuralgia is a neuropathic facial pain condition which is characterised by unilateral paroxysmal pain which is excruciating, short lasting in the distribution territory of trigeminal nerve.(1) Trigeminal neuralgia is oro-facial pain restricted to one or more divisions of the trigeminal nerve. With the exception of Trigeminal Neuralgia caused by Multiple sclerosis, the pain affects one side of the face. It is abrupt in onset and typically lasts only a few seconds (2 min at maximum).Patients may report their pain as arising spontaneously, but these pain paroxysms can always be triggered by innocuous mechanical stimuli or movements. Patients usually do not experience pain between paroxysms. If they do report additional continuous pain, in the same distribution and in the same periods as the paroxysmal pain, they are considered to have Trigeminal Neuralgia with continuous pain. (IASP)(1) Trigeminal neuralgia is mainly classified into three diagnostic categories i.e. Classical, Secondary and Idiopathic. This classification is mainly based on the etiology \& pain characteristics. The etiology of Trigeminal Neuralgia is not well understood, but various theories such as Compression of sensory root of trigeminal nerve by arteries \& bony exostoses.(4) ,focal demyelination of trigeminal afferents near the entry of the trigeminal root into pons(2)and alteration in the central neural function followed by injury to peripheral nerves (4) are widely accepted.

Trigeminal Neuralgia has a profound effect on quality of life of the patient \& expenditure on health (4). Due to the severe intensity of pain, patients avoid touching face, washing face, thus making patient's life disturbing \& miserable. Even after so many years of research, it is still a challenge to treat patients suffering from Trigeminal Neuralgia. Treatment can be sub- divided into pharmacological \& invasive therapies .

The pharmacological therapy include drugs such as carbamazepine ( 200-1200mg) , oxcarbazepine (300-1800mg) , lamotrigine, Gabapentin , baclofen, eslicarbazepine, sumatriptan, vixotrigine. The pre- surgical procedures like botulinium toxin A \& intranasal non-inhaled CO2 have also been sporadically used (1).

A review study discussing the pharmacological options to treat trigeminal neuralgia concluded that carbamazepine \& oxcarbazepine are the first choice of drugs(1). Oxcarbazepine showed equal efficacy in reducing pain attacks with better tolerability \& less side effects (1) .

A recently conducted study found that carbamazepine is associated with serious side effects including CNS disturbances, somnolence, unbalance, thrombocytopenia, increase level of transaminases while OXC showed similar efficacy with less side effects. CNS disturbances encountered in patients on CBZ were triple to those on OXC \& withdrawal from the treatment was also more in patients on CBZ(27%) than on OXC (18%)(12).

OXC has contemporarily been used as monotherapy in epileptic patients (8) \& has proven efficacy over the CBZ. In trigeminal neuralgia, though various studies have shown that OXC produce lesser side effects, but none of the studies have compared the efficacy of carbamazepine with oxcarbazepine .

Thus the present study intends to compare the efficacy of oxcarbazepine with carbamazepine as monotherapy in patients suffering from trigeminal neuralgia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Trigeminal Neuralgia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oxcarbazepine GROUP

Oxcarabazepine 150mg BD starting dose \& will be increased if the patient is not relieved

Group Type EXPERIMENTAL

Oxcarbazepine

Intervention Type DRUG

oxcarbazepine 150mg BD initial dose , followup will be done at 15days, 6weeks, 10 weeks interval

Carbamzepine GROUP

carbamazepine 100mg BD initial dose \& will be increased if the patient is not relieved

Group Type ACTIVE_COMPARATOR

Carbamazepine

Intervention Type DRUG

carbamazepine 100mg BD initial dose, follow up will be done 2weeks, 6 weeks \& 10weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oxcarbazepine

oxcarbazepine 150mg BD initial dose , followup will be done at 15days, 6weeks, 10 weeks interval

Intervention Type DRUG

Carbamazepine

carbamazepine 100mg BD initial dose, follow up will be done 2weeks, 6 weeks \& 10weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LOVAX zileuton

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinically proven cases of primary trigeminal neuralgia.
* Patients who are willing to participate in the study.

Exclusion Criteria

* Intolerance to either of the two drugs
* Medically compromised patients
* Patients with pacemaker
* Patients who have previously undergone surgical treatment for TRIGEMINAL NEURALGIA.
* Patients who are already on pharmacotherapy for TRIGEMINAL NEURALGIA.
* Seizure disorder/ pregnant/ lactating
* Renal/ hepatic impairment
* History of hyponatermia
* Concurrent medication- dilantin, phenytoin
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Postgraduate Institute of Dental Sciences Rohtak

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

PGIDS

Rohtak, Haryana, India

Site Status RECRUITING

Post Graduate Institute of Dental Sciences

Rohtak, Haryana, India

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

India

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sanjay Tewari, MDS

Role: CONTACT

[email protected]
01262283876

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Dr. Sanjay Tewari, MDS

Role: primary

[email protected]
01262283876

SANJAY TEWARI, MDS

Role: primary

[email protected]
01262283876

AMBIKA GUPTA

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

suman008

Identifier Type: -

Identifier Source: org_study_id